#USA #San Diego #Class Action #Securities Fraud #Regeneron

Regeneron Pharmaceuticals Invites Investors to Join Class Action Lawsuit

In a significant development for investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), a class action lawsuit has been initiated aimed at addressing substantial losses suffered during a defined period. The law firm Robbins Geller Rudman & Dowd LLP has extended an invitation to those who acquired Regeneron securities from November 2, 2023, through October 30, 2024, to consider leading the class action lawsuit.

The class action, titled Radtke v. Regeneron Pharmaceuticals, Inc., claims that the company, along with some members of its current and former executive staff, engaged in activities that violated the Securities Exchange Act of 1934. For potential lead plaintiffs, the deadline to act is March 10, 2025.

Allegations Following Sales Practices of Eylea

At the heart of the lawsuit are accusations surrounding Regeneron’s pricing practices, particularly concerning their prominent product, Eylea, an injectable treatment for various eye conditions. Notably, the allegations suggest that the company failed to disclose certain financial arrangements that effectively altered the pricing landscape of Eylea.

Among the critical claims made are assertions that Regeneron compensated distributors for credit card processing fees under the condition that they would not pass these additional costs onto customers purchasing Eylea. This tactic is argued to have allowed Regeneron to offer lower selling prices, consequently boosting reported sales figures misleadingly throughout the class period.

The lawsuit also states the company inaccurately reported the Average Sales Price (ASP) to federal agencies, potentially violating the False Claims Act and inflating its profile in the marketplace. In essence, these practices provided Regeneron with an undue competitive edge over other similar treatments for age-related conditions.

Regulatory Scrutiny and Market Impact

The implications of the accusations were heightened on April 10, 2024, when the U.S. Department of Justice (DOJ) intervened, asserting that Regeneron had not disclosed millions in discounts linked to these credit card reimbursements. This judicial scrutiny led to an observable decline in Regeneron’s stock price, raising concerns among investors.

Further complicating matters, the company’s financial report released on October 31, 2024, reflected reduced sales for Eylea and Eylea HD, indicating a mere 3% increase in net sales from the previous year, which fell below anticipated forecasts. Following this announcement, Regeneron’s stock suffered an additional drop, further underscoring the alleged consequences of deceptive financial practices.

Navigating the Lead Plaintiff Process

For investors seeking to participate in the Regeneron class action, the lead plaintiff process allows those who face significant financial losses to be appointed to represent the collective interests of other plaintiffs. This role enables lead plaintiffs to help steer the course of the litigation and select a law firm of their preference to handle their case. Importantly, individual recovery in this lawsuit is not dependent on taking on the lead plaintiff designation, a detail designed to foster broader participation.

About Robbins Geller Rudman & Dowd LLP

Robbins Geller is noted for its efforts in securities fraud litigation, having successfully secured a staggering $6.6 billion for investors through class action lawsuits, highlighting its reputation in the field. The firm has maintained a noteworthy presence in investor representation, advocating tirelessly for shareholders who have suffered from misleading corporate practices.

In conclusion, the Regeneron case represents a crucial moment for investors seeking justice in the financial marketplace. Those aligned with Regeneron during the class period may find an opportunity to recover losses through this ongoing litigation initiative. For more information on joining the lawsuit or about the firm itself, potential investors can reach out to Robbins Geller via their official channels.

For direct inquiries, investors can contact attorneys J.C. Sanchez or Jennifer N. Caringal at Robbins Geller, or visit their website to learn more about the proceedings. Investors are urged to take swift action to ensure their voices are heard in this pivotal case.